Background. It has been observed that immune responses to vaccination can vary between populations, in particular that immune responses to Haemophilus influenzae type b (Hib) vaccines are lower in certain ethnic groups. This study was undertaken to assess the immune response of Canadian Aboriginals (First Nations, Inuit, Métis) to the Hib and hepatitis B virus (HBV) components of the combined hexavalent diphtheria, tetanus, acellular pertussis, HBV, inactivated poliovirus and Hib vaccine (DTPa-HBV-IPV/Hib; GlaxoSmithKline Vaccines).
Methods.
Phase IV, open-label, parallel-group study conducted at 3 centers in Canada (NCT00753649). Healthy Aboriginal and non-Aboriginal infants received DTPa-HBV-IPV/Hib at 2, 4 and 6 months of age. Immune responses to Hib polyribosyl ribitol phosphate (PRP) and HBV surface antigen (HBs) were measured 1 month post-dose 3. Medically-attended and serious adverse events (MAAEs/SAEs) were recorded up to 1 month post-dose 3.
Results. Seroprotection against Hib and HBV, 1 month post-dose 3, was comparable in the 94 Aboriginal and 107 non-Aboriginal infants included in the per-protocol analysis (Table) . Anti-PRP antibody geometric mean concentrations (GMCs) were 1.7 fold higher in Aboriginal infants (Table) .
Seroprotection rates and GMCs for Hib and HBV, with 95% confidence intervals

Aboriginal
Non-Aboriginal
Hib PRP % ≥0.15 µg/ml 97.9 (92.5-99.7) 99.1 (94.9-100) % ≥1 µg/ml 88.3 (80.0-94.0) 85.0 (76.9-91.2) GMC (µg/ml) 6.1 (4.5-8.3) 3.5 (2.7-4.5) HBs % ≥10 mIU/ml 100 (96.0-100) 100 (96.5-100) GMC (mIU/ml) 1797.9 (1375.1-2350.7) 1544. 4 (1210.4-1970.5) 23.2% Aboriginal and 17.0% non-Aboriginal infants recorded MAAEs. 7 SAEs (bronchiolitis, pyrexia, bacterial pneumonia, respiratory syncytial virus infection and 3 cases of convulsion) were recorded in 6 Aboriginal infants; only 1 case ( pyrexia) was assessed as vaccine-related; all SAEs had resolved by study end.
Conclusion. 3-dose primary vaccination with DTPa-HBV-IPV/Hib elicited immune responses to the Hib and HBV antigens that were at least as high in Aboriginal as in non-Aboriginal Canadian infants. No safety concerns were identified.
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